MOLECULAR TEMPLATES INC (MTEM) Stock Price, Quote, News and Overview
NASDAQ:MTEM - Nasdaq - US6085502085 - Common Stock - Currency: USD
MTEM Quote, Performance and Key Statistics
0.1072
-0.03 (-23.43%)
The current stock price of MTEM is 0.1072 USD. In the past month the price decreased by -73.31%. In the past year, price decreased by -97.13%.
MTEM Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About MTEM
Company Profile
Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. The company is headquartered in Austin, Texas and currently employs 62 full-time employees. The company went IPO on 2005-02-04. The Company’s proprietary drug platform technology, known as engineered toxin bodies (ETBs), leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer. Its product pipeline includes MT-6402, MT-8421 and MT-0169. MT-6402 is an ETB consisting of a single chain variable fragments (scFv), with affinity for PD-L1, fused to the enzymatically active de-immunized SLTA and a HLA-A*02 class I antigen derived from the human cytomegalovirus (HCMV) pp65 protein. MT-8421, its ETB targeting CTLA-4, along with MT-6402. MT-0169 is designed to destroy CD38+ tumour cells through internalization of CD38 and cell destruction via a novel mechanism of action (enzymatic ribosomal destruction and immunogenic cell death).
Company Info
MOLECULAR TEMPLATES INC
9301 Amberglen Blvd, Suite 100
Austin TEXAS 78729 US
CEO: Eric E. Poma
Employees: 62
Company Website: https://www.mtem.com/
Investor Relations: https://www.mtem.com/investors
Phone: 15128961555
MOLECULAR TEMPLATES INC / MTEM FAQ
What is the stock price of MOLECULAR TEMPLATES INC today?
The current stock price of MTEM is 0.1072 USD. The price decreased by -23.43% in the last trading session.
What is the ticker symbol for MOLECULAR TEMPLATES INC stock?
The exchange symbol of MOLECULAR TEMPLATES INC is MTEM and it is listed on the Nasdaq exchange.
On which exchange is MTEM stock listed?
MTEM stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MOLECULAR TEMPLATES INC stock?
7 analysts have analysed MTEM and the average price target is 18.36 USD. This implies a price increase of 17026.87% is expected in the next year compared to the current price of 0.1072. Check the MOLECULAR TEMPLATES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MOLECULAR TEMPLATES INC worth?
MOLECULAR TEMPLATES INC (MTEM) has a market capitalization of 705.38K USD. This makes MTEM a Nano Cap stock.
How many employees does MOLECULAR TEMPLATES INC have?
MOLECULAR TEMPLATES INC (MTEM) currently has 62 employees.
Is MOLECULAR TEMPLATES INC (MTEM) expected to grow?
The Revenue of MOLECULAR TEMPLATES INC (MTEM) is expected to decline by -78.76% in the next year. Check the estimates tab for more information on the MTEM EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy MOLECULAR TEMPLATES INC (MTEM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MTEM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MTEM, evaluating the profitability, health, valuation and growth aspects
- MOLECULAR TEMPLATES INC (MTEM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MOLECULAR TEMPLATES INC (MTEM) Sales and EPS estimates to see what analysts future expectations are.
- MOLECULAR TEMPLATES INC (MTEM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MOLECULAR TEMPLATES INC (MTEM) Insider and Institutional Ownership to learn about the owners and their transactions.
- MOLECULAR TEMPLATES INC (MTEM) Stock Chart to make your own analysis
- MOLECULAR TEMPLATES INC (MTEM) Latest news and press-releases to stay up to date.
Does MOLECULAR TEMPLATES INC (MTEM) stock pay dividends?
MTEM does not pay a dividend.
What is the Price/Earnings (PE) ratio of MOLECULAR TEMPLATES INC (MTEM)?
MOLECULAR TEMPLATES INC (MTEM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.7).
What is the Short Interest ratio of MOLECULAR TEMPLATES INC (MTEM) stock?
The outstanding short interest for MOLECULAR TEMPLATES INC (MTEM) is 0.88% of its float. Check the ownership tab for more information on the MTEM short interest.
MTEM Technical Analysis
MTEM Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MTEM. While MTEM seems to be doing ok healthwise, there are quite some concerns on its profitability.
MTEM Financial Highlights
Over the last trailing twelve months MTEM reported a non-GAAP Earnings per Share(EPS) of -2.7. The EPS increased by 78.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -58.52% | ||
| ROE | -219.7% | ||
| Debt/Equity | 0 |
MTEM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to MTEM. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of -92.81% and a revenue growth -78.76% for MTEM